S&P 500
(0.84%) 5 290.64 points
Dow Jones
(0.66%) 39 820 points
Nasdaq
(0.96%) 16 670 points
Oil
(0.10%) $78.10
Gas
(0.00%) $2.34
Gold
(1.17%) $2 387.40
Silver
(3.23%) $29.63
Platinum
(2.53%) $1 071.00
USD/EUR
(-0.42%) $0.920
USD/NOK
(-0.79%) $10.71
USD/GBP
(-0.58%) $0.790
USD/RUB
(-0.70%) $90.68

Realtime updates for Sutro Biopharma Inc [STRO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-05-20)

Expected move: +/- 9.02%

BUY
100.00%
return 8.99%
SELL
28.57%
return 12.32%
Last Updated15 May 2024 @ 11:22

-2.30% $ 4.24

BUY 130873 min ago

@ $4.45

Issued: 14 Feb 2024 @ 13:11


Return: -4.74%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: -4.28 %

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 11:22):
Profile picture for Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+...

Stats
Today's Volume 150 648
Average Volume 984 845
Market Cap 346.68M
EPS $0 ( 2024-04-04 )
Next earnings date ( $-0.920 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.38
ATR14 $0.00800 (0.19%)
Insider Trading
Date Person Action Amount type
2024-05-01 Srinivasan Venkatesh Buy 2 500 Common Stock
2024-05-01 Srinivasan Venkatesh Sell 892 Common Stock
2024-05-01 Srinivasan Venkatesh Sell 2 500 Restricted Stock Unit (RSU)
2024-04-11 Srinivasan Venkatesh Sell 21 250 Restricted Stock Unit (RSU)
2024-04-11 Srinivasan Venkatesh Buy 21 250 Common Stock
INSIDER POWER
67.41
Last 99 transactions
Buy: 2 156 384 | Sell: 407 712

Volume Correlation

Long: 0.20 (neutral)
Short: 0.80 (moderate)
Signal:(35.773) Neutral

Sutro Biopharma Inc Correlation

10 Most Positive Correlations
TNGX0.88
CARA0.864
EYE0.821
SLM0.809
ACHC0.801
LSXMK0.801
10 Most Negative Correlations
ALR-0.839
INZY-0.833
BTBD-0.83
INOD-0.828
GETVV-0.826
HYPR-0.824
FTIV-0.812
OCUL-0.803
SELF-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sutro Biopharma Inc Correlation - Currency/Commodity

The country flag 0.08
( neutral )
The country flag 0.77
( moderate )
The country flag 0.00
( neutral )
The country flag -0.53
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.67
( moderate negative )

Sutro Biopharma Inc Financials

Annual 2023
Revenue: $153.73M
Gross Profit: $146.92M (95.57 %)
EPS: $-1.780
FY 2023
Revenue: $153.73M
Gross Profit: $146.92M (95.57 %)
EPS: $-1.780
FY 2022
Revenue: $67.77M
Gross Profit: $59.48M (87.77 %)
EPS: $-2.35
FY 2021
Revenue: $61.88M
Gross Profit: $61.88M (100.00 %)
EPS: $-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc Options Data

Array
Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators